Showing 2761-2770 of 3190 results for "".
- New Research Suggests Why PD-1 Blockers Don't Work for All Melanoma Patientshttps://practicaldermatology.com/news/new-research-suggests-why-pd-1-blockers-dont-work-for-all-melanoma-patients/2458645/Immunotherapy using anti-PD-1 antibodies has been a game change for metastatic melanoma patients, but 60 to 70 percent of patients’ melanoma tumors are resistant to the anti-PD-1 antibodies. Now new research out of UCLA suggests that patterns of gene
- Coming Soon: Olay Eyes To Hit Stores in July 2016https://practicaldermatology.com/news/coming-soon-olay-eyes-to-hit-stores-in-july-2016/2458656/Olay is getting set to launch Olay Eyes, a new line exclusively for the skin around the eyes. Slated to hit store shelves in July 2016, the new line will include four specific products that address the different ways eyes can age: dark circles, bagg
- New from Olay: Regenerist Micro-Sculpting Cream with SPF 30https://practicaldermatology.com/news/new-from-olay-regenerist-micro-sculpting-cream-with-spf-30/2458657/Olay introduced the newest member of the Regenerist family -- Regenerist Micro-Sculpting Cream with SPF 30 -- at the annual meeting of the American Academy of Dermatology in Washington, DC. Several studies presented here helped lay the groundw
- Lumenis Supports the Launch of Restoring Heroes Foundation for Scar Patientshttps://practicaldermatology.com/news/lumenis-launches-restoring-heroes-foundation-for-scar-patients/2458658/Kim Phuc, the young girl who was immortalized in a photograph taken during the 1972 Napalm bombing, has come a long way since that fateful day. When the photo was taken, she was running away from her village, naked, after her clothing had been burnt off. South Vietnamese plane
- Khloé Kardashian Kicks Off Kybella Campaign in NYChttps://practicaldermatology.com/news/khlo-kardashian-kicks-off-kybella-campaign-in-nyc/2458669/Khloé Kardashian helped Allergan plc kick off their new Live Chin Up campaign. The campaign is designed to help encourage people to not let the things that bother them get in their way. At the event, Kardashian moderated a panel of experts who discussed submental fullnes
- Dermwire's Inside Scoop on Hottest Expected AAD2016 Launcheshttps://practicaldermatology.com/news/dermwires-inside-scoop-on-hottest-expected-aad2016-launches/2458670/The American Academy of Dermatology (AAD)’s annual meeting is the place for skin care companies looking to launch the latest – and hopefully greatest --- innovations or iterations in skin care products and technologies. And the
- Practical Dermatology® Launches #PDGivesBack to Support Camp Discovery at AAD 2016https://practicaldermatology.com/news/practical-dermatology-launches-pdgivesback-to-support-camp-discovery-at-aad-2016/2458672/Bryn Mawr Communications III’s Practical Dermatology® magazine is inviting attendees at the 74th Annual Meeting of the American Academy of Dermatology (AAD) to give back as part of its new “selfless-selfies” campaign.
- Valeant Dermatology Launches Aspire Higher Scholarship Programhttps://practicaldermatology.com/news/valeant-dermatology-launches-aspire-higher-scholarship-program/2458676/Valeant Dermatology, a division of Valeant Pharmaceuticals North America LLC, launched Valeant Dermatology ASPIRE HIGHER Scholarship Program that will award scholarships of up to $10,000 each to nine individual students who will be attending an undergraduate or graduate education program during t
- WHO: Improved Access to Psoriasis Treatments Neededhttps://practicaldermatology.com/news/who-improved-access-to-psoriasis-treatments-needed/2458685/Key stakeholders including policy makers, physicians and patients must come together to turn the corner on psoriasis, according to the World Health Organization’s (WHO) new Globa
- NOVAN: First Patient Dosed in Phase 3 Program for SB204https://practicaldermatology.com/news/novan-first-patient-dosed-in-phase-3-program-for-sb204/2458688/The first patient has been dosed in a Phase 3 study of Novan’s investigational topical nitric oxide acne gel, Novan, Inc. reports. Novan is running two identically designed Phase 3 pivotal trials in parallel to evaluate the effic